Φορτώνει......
Long-responders to anti-HER2 therapies: A case report and review of the literature
Since the introduction of targeted therapies, prognosis in human epidermal growth factor receptor (HER) 2-positive metastatic breast cancer (MBC) has radically changed. The addition of Pertuzumab to Trastuzumab and standard chemotherapy has further increased patients' overall survival (OS). How...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Mol Clin Oncol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
D.A. Spandidos
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5769304/ https://ncbi.nlm.nih.gov/pubmed/29387408 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2017.1495 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|